pathology | Benefit (demonstrated or suggested) and harm | |||
---|---|---|---|---|
atrial fibrillation | All results are NS for efficacy inferior to warfarin standard dose in terms of non fatal bleeding in AMADEUS, 2008 inferior to warfarin standard dose in terms of all bleeding in AMADEUS, 2008 inferior to warfarin standard dose in terms of major bleeding in AMADEUS, 2008 inferior to warfarin standard dose in terms of fatal bleeding in AMADEUS, 2008 | meta-analysis | ||
pulmonary embolism | All results are NS for efficacy inferior to heparin/VKA in terms of All deaths in VanGogh PE, 2007 inferior to heparin/VKA in terms of non fatal PE in VanGogh PE, 2007 inferior to heparin/VKA in terms of recurrent VTE in VanGogh PE, 2007 | meta-analysis | ||
venous thrombosis | All results are NS for efficacy inferior to heparin/VKA in terms of All deaths in VanGogh PE, 2007 inferior to heparin/VKA in terms of non fatal PE in VanGogh PE, 2007 inferior to heparin/VKA in terms of recurrent VTE in VanGogh PE, 2007 | meta-analysis |